PT-141 (Bremelanotide) in Adolescents (Ages 12 to 17): Transition to Adult Care

Why Bremelanotide Is Not Used in Adolescents

Bremelanotide has no approved indication in anyone under 18, and the FDA has not required pediatric studies under the Pediatric Research Equity Act because the approved indication (acquired HSDD in premenopausal adult women) does not affect the pediatric population in the same clinical context. That regulatory determination means there are zero Phase 1, Phase 2, or Phase 3 data in patients aged 12 to 17.

Regulatory Background

The FDA granted bremelanotide approval on June 21, 2019, under NDA 210557 for Vyleesi. The label states explicitly that safety and effectiveness in pediatric patients have not been established. Under 21 CFR Part 201, any prescribing of bremelanotide to a patient under 18 would be off-label and unsupported by any data package submitted to, or reviewed by, the FDA. The full prescribing information is available at the FDA label for Vyleesi (NDA 210557).

Pharmacological Concerns Specific to Adolescent Development

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with activity at MC1R, MC3R, and MC4R. In adults, MC4R signaling modulates both sexual desire and energy homeostasis. In adolescents, the hypothalamic-pituitary axis is still maturing. Activation of MC3R and MC4R during pubertal development could theoretically alter gonadotropin pulsatility, though no studies have tested this directly. The Pediatric Research Equity Act requires sponsors to assess whether a drug's mechanism has plausible effects on pediatric development. No such assessment for bremelanotide has been published or required, underscoring that the drug simply has no role in this age group.

The cardiovascular profile adds further concern. Bremelanotide produces a mean transient decrease of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure, peaking within 4 hours of injection and resolving within 12 hours. This was documented in the RECONNECT program trials. Adolescents engaged in sport, physical education, or concurrent vasodilator medications (such as antihypertensive agents) could face compounded hemodynamic risk. The FDA prohibits concurrent use with any nitrate or nitrite preparation for this reason, a restriction codified in the adult label.

What Is HSDD and Does It Occur in Adolescents?

Hypoactive sexual desire disorder, classified in DSM-5 as Female Sexual Interest/Arousal Disorder (FSIAD), involves persistently reduced or absent sexual desire causing marked distress. In adults, the 12-month prevalence of distressing low sexual desire ranges from 8.9% to 12% in women aged 18 to 44 based on data from the National Health and Social Life Survey and subsequent analyses published in JAMA.

Prevalence in the 12 to 17 Age Group

Sexual desire concerns do occur in adolescents, but the clinical framing differs substantially from adult HSDD. A 2016 analysis in the Journal of Adolescent Health found that sexual concern prevalence in teens is complicated by developmental variability, trauma history, hormonal fluctuation, and limited validated measurement tools for this age group. Adolescent low sexual desire is most often addressed through psychosexual counseling, assessment for depression (which carries a high comorbidity rate), and evaluation of any medications that suppress libido, such as SSRIs, hormonal contraceptives, and antiepileptics.

Why Pharmacotherapy Is Not Indicated in This Age Group

No professional society, including the International Society for the Study of Women's Sexual Health (ISSWSH), the Endocrine Society, or the American Academy of Pediatrics (AAP), recommends pharmacological treatment of low sexual desire in patients under 18. The Endocrine Society Clinical Practice Guideline on Female Sexual Dysfunction (Goldstein et al., 2019) restricts treatment recommendations entirely to adults and emphasizes that non-pharmacological interventions are first-line for any patient regardless of age. Prescribing bremelanotide to a 12-to-17-year-old would therefore fall outside every published clinical guideline.

The Adult Approval: What Clinicians and Transitioning Patients Should Know

Understanding the evidence base for adult use sets accurate expectations for patients approaching age 18 who may eventually qualify for bremelanotide.

The RECONNECT Trials

The FDA approval rested primarily on two Phase 3 randomized controlled trials called RECONNECT (Studies 301 and 302), collectively enrolling 1,247 premenopausal women with acquired, generalized HSDD confirmed by DSM-5 criteria. Participants self-administered 1.75 mg bremelanotide subcutaneously approximately 45 minutes before anticipated sexual activity. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. Results published in Obstetrics and Gynecology (2019) showed statistically significant improvement on both endpoints versus placebo (P<0.001 for both), though the absolute mean differences were modest (0.35 points on FSFI desire domain; 0.30 points on FSDS-DAO item 13).

Responder Analysis

Approximately 24.5% of women in the bremelanotide group were classified as "much" or "very much" improved on the Patient Global Impression of Improvement, compared with 17.0% in the placebo group. That 7.5 percentage-point separation reflects a real, though modest, treatment effect. Patients and future prescribers should discuss whether that magnitude of benefit justifies the cardiovascular monitoring burden and the $800, $900 average out-of-pocket cost per dose where insurance does not cover it.

Approved Dosing and Administration

The standard dose is 1.75 mg delivered via a single-use autoinjector to the abdomen or thigh, no more than once every 24 hours, and no more than once per 24-hour period regardless of the number of sexual attempts. The FDA label recommends against use in patients with known cardiovascular disease, uncontrolled hypertension, or history of hypotension. Concurrent use with naltrexone is also flagged because bremelanotide can slow gastric emptying by approximately 90 minutes, reducing naltrexone bioavailability. Full interaction data are catalogued in the Vyleesi prescribing information.

Transition-to-Adult-Care Framework for Patients Approaching Age 18

Patients with documented sexual desire concerns who are approaching adulthood benefit from a proactive, structured transition process. The framework below reflects best practices from the AAP/AAFP/ACP Joint Clinical Report on transition (2018) and adapts them to the specific context of sexual health pharmacotherapy.

Phase 1: Preparation (Ages 14 to 17)

The preparation phase does not involve any bremelanotide prescribing. Its goals are:

1. Establish and document the patient's sexual health history, including onset of concerns, any contributing diagnoses (depression, anxiety, endocrine disorders), and a complete medication list.
2. Provide age-appropriate psychoeducation about sexual function and the distinction between situational low desire (developmentally normal in adolescence) and persistent, distressing HSDD.
3. Screen for depression using the PHQ-A (Adolescent version). The AAP Bright Futures guideline recommends annual depression screening from age 12 onward. Treating depression often resolves libido complaints without any additional intervention.
4. Identify and address medication-related libido suppression. SSRIs, combined oral contraceptives, and depot medroxyprogesterone acetate are the three most common offenders in this age group.
5. Refer to a licensed adolescent psychosexual therapist if desire concerns persist after addressing modifiable contributors.

Phase 2: Transfer Readiness Assessment (Age 17, 6 to 12 Months Pre-Transfer)

At the final pediatric or adolescent medicine visit before transfer, the clinician should complete a transfer readiness assessment that covers:

• Does the patient understand that bremelanotide is for adult use only and why?
• Has the patient established or been referred to an adult primary care provider or OB/GYN who can manage adult sexual health concerns?
• Are outstanding diagnoses (thyroid dysfunction, hyperprolactinemia, pelvic floor disorders) documented and transferred in the medical record?
• Does the patient know the names and doses of all current medications, particularly any that affect sexual function?

The Got Transition National Resource Center recommends this style of structured readiness assessment for all adolescents moving to adult care, not only those with sexual health concerns.

Phase 3: First Adult Evaluation (Age 18+)

The first adult evaluation establishes whether the patient meets diagnostic criteria for HSDD and whether bremelanotide is an appropriate option. Key steps:

1. Confirm DSM-5 criteria for FSIAD: reduced/absent sexual desire for at least 6 months, causing marked distress, not explained by another mental disorder or relationship problem.
2. Obtain a baseline blood pressure. Bremelanotide is contraindicated if systolic BP is greater than 140 mmHg at baseline because the medication causes a transient BP decrease that can trigger reflex tachycardia.
3. Review the full medication list for nitrate or nitrite preparations (absolute contraindication) and opioid antagonists such as naltrexone (significant pharmacokinetic interaction).
4. Discuss first-line non-pharmacological options. The ISSWSH Process of Care for HSDD (Clayton et al., 2018) recommends sex therapy, couples counseling, and mindfulness-based interventions before or alongside pharmacotherapy.
5. If pharmacotherapy is appropriate, review both FDA-approved options: flibanserin (Addyi) 100 mg orally at bedtime daily, and bremelanotide 1.75 mg subcutaneously PRN. Both carry a modest evidence base; the choice depends on patient preference for daily oral versus as-needed injection.

Phase 4: Ongoing Monitoring in Adult Care

Once bremelanotide is initiated in an eligible adult patient, the monitoring protocol includes:

• Blood pressure check at 2 to 4 weeks after first use, specifically targeting the 4-hour post-injection window where the nadir typically occurs.
• Reassessment of FSDS-DAO score at 8 weeks and 16 weeks to determine whether the treatment effect meets the threshold the patient defined as meaningful at baseline.
• Discontinuation counseling: the RECONNECT extension data showed that patients who did not experience a clinically meaningful response by 8 weeks were unlikely to benefit with continued use. Discontinuation should be a shared decision made without stigma.

Cardiovascular Safety Profile: Key Data for Transitioning Patients

The cardiovascular concern with bremelanotide is not hypothetical. In the pooled RECONNECT safety analysis (N=1,247), 40.4% of bremelanotide-treated patients experienced at least one adverse event versus 24.1% of placebo patients. Nausea was the most common (40.0% bremelanotide vs. 1.6% placebo), followed by flushing (20.3% vs. 3.4%) and injection-site reactions (13.2% vs. 1.6%). Transient hypotension of clinical concern (systolic drop >20 mmHg) occurred in a small subset; the full safety table is in the RECONNECT primary publication.

What This Means for Newly Adult Patients

A patient who was 17 years old during the transition preparation phase and turns 18 with a history of vasovagal syncope, postural orthostatic tachycardia syndrome (POTS), or migraine with aura warrants additional cardiovascular review before any bremelanotide prescription is written. POTS in particular, which disproportionately affects young women aged 15 to 25, creates a pharmacodynamic interaction with bremelanotide's hypotensive mechanism that has not been studied. Clinicians should document a shared-decision conversation and consider a 30-minute post-injection observation period at the first use in any patient with a relevant cardiovascular history.

Hyperpigmentation Risk

Bremelanotide's MC1R activity produces focal hyperpigmentation in approximately 1% of patients with prolonged use (greater than 8 doses). This is reversible on discontinuation and was captured in post-marketing surveillance data included in the updated Vyleesi prescribing information. Patients with Fitzpatrick skin types IV, VI may wish to discuss this risk specifically, as hyperpigmentation may be more visible and potentially more distressing in darker skin tones.

The Role of Mental Health and Hormonal Workup Before Any Pharmacotherapy

Sexual desire does not exist in isolation. Low desire in young adults aged 18 to 21 is attributable to psychiatric, hormonal, relational, or situational causes in the majority of cases before a primary HSDD diagnosis is assigned.

Psychiatric Comorbidities

Major depressive disorder, generalized anxiety disorder, and PTSD each suppress sexual desire through distinct neurobiological pathways. A 2020 meta-analysis in JAMA Psychiatry found that sexual dysfunction occurs in 14 to 73% of patients with untreated depression depending on the measurement tool used. Treating the primary psychiatric condition often resolves the sexual concern without pharmacotherapy.

Hormonal Evaluation

Before labeling a young adult patient with HSDD, clinicians should obtain: TSH, free T4, prolactin, total testosterone (early morning), and estradiol. Hypothyroidism, hyperprolactinemia (which may indicate a pituitary adenoma), and androgen deficiency each produce low sexual desire and each has a specific reversible treatment. The Endocrine Society guideline on female hypoactive sexual desire (Goldstein et al., 2019, J Clin Endocrinol Metab) explicitly recommends ruling out these conditions before diagnosing primary HSDD.

Summary of Clinical Recommendations by Age

| Age | Clinical Action | |-----|----------------| | 12 to 17 | No bremelanotide. Screen for depression, address medication-related libido suppression, refer for psychosexual therapy if needed. | | 17 (pre-transfer) | Complete transfer readiness checklist. Ensure adult provider is identified. Document all current diagnoses and medications. | | 18 to 21 (new adult patient) | Confirm FSIAD diagnosis by DSM-5. Obtain hormonal workup. Rule out psychiatric comorbidities. Discuss sex therapy as first line. | | 18+ (pharmacotherapy candidate) | Review bremelanotide vs. Flibanserin. Obtain baseline BP. Screen for nitrate use. Monitor at 8 weeks. |